Considerations for addressing bias in artificial intelligence for health equity
University of Iowa · United States Food and Drug Administration · +7 more institutions
Abstract
Health equity is a primary goal of healthcare stakeholders: patients and their advocacy groups, clinicians, other providers and their professional societies, bioethicists, payors and value based care organizations, regulatory agencies, legislators, and creators of artificial intelligence/machine learning (AI/ML)-enabled medical devices. Lack of equitable access to diagnosis and treatment may be improved through new digital health technologies, especially AI/ML, but these may also exacerbate disparities, depending on how bias is addressed. We propose an expanded Total Product Lifecycle (TPLC) framework for healthcare AI/ML, describing the sources and impacts of undesirable bias in AI/ML systems in each phase,…
Citation impact
- FWCI
- 10.37
- Percentile
- 100%
- References
- 41
Authors
8- MDMichael D. AbràmoffCorresponding
University of Iowa
- MEMichelle E. Tarver
United States Food and Drug Administration, Center for Devices and Radiological Health
- NLNilsa Loyo‐Berríos
United States Food and Drug Administration, Center for Devices and Radiological Health
- STSylvia Trujillo
Ochin
- DCDanton Char
University of California, San Francisco, Ethics and Public Policy Center, San Diego Cardiac Center, Stanford University
Topics & keywords
- Equity (law)
- Health care
- Health equity
- Business
- Digital health
- Public relations
- Order (exchange)
- Risk analysis (engineering)